Journal
EXPERT OPINION ON DRUG DELIVERY
Volume 17, Issue 7, Pages 899-902Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2020.1772229
Keywords
COVID-19; SARS-CoV-2; coronavirus; three-dimensional printing; oral solid dosage forms; epidemic; pandemic; drug supply chain; distributed manufacturing
Categories
Funding
- Austrian Competence Centres for Excellent Technologies (COMET) programme
- Federal Ministry for Digital and Economic Affairs (BMDW)
- Land Steiermark
- Styrian Business Development Agency (SFG)
Ask authors/readers for more resources
The ongoing COVID-19 crisis has highlighted the importance of a robust drug supply chain which can be quickly and flexibly ramped up to produce life-saving drug treatments. 3D printing (3DP) of oral solid dosage forms (OSDF) could be a viable part of the emergency drug production response to support vulnerable patients in rural regions and other isolated locations. In the context of the current pandemic, the suitability of different 3DP technologies will depend on the physicochemical properties, unit dose strength and BCS classification of the repurposed drug compounds currently being trialed for COVID-19. Furthermore, the deployment strategy should focus on simplifying dosage forms and formulations, scaling down the size and complexity of the printing systems and real-time quality assurance via process analytical technologies (PAT).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available